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A single 9-MeV electron treatment, following invasive thoracic procedures in patients with malignant pleural mesothelioma, was
examined. In all, 58 sites were randomised to prophylactic radiotherapy or not. There was no statistically significant difference in tract
metastasis. A single 10-Gy treatment with 9-MeV electrons appears ineffective.
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In recent years, the incidence of malignant pleural mesothelioma
(MPM) has been increasing rapidly (Peto et al, 1999). Chest wall
seeding following invasive procedures is a problem, and has been
reported to occur in 19% of patients following thoracoscopy
(Boutin et al, 1995). These subcutaneous masses are often
symptomatic and refractory to radiotherapy (RT) (Davis et al,
1994). Two nonrandomised series and one randomised controlled
trial have demonstrated that a prophylactic three-fraction course
of RT reduces the procedure tract metastasis rate to 0% (Boutin
and Rey, 1993; Boutin et al, 1995; Low et al, 1995). Recent reviews
and guidelines recommended prophylactic radiotherapy following
thoracic procedures (BTSSCC, 2001; Parker and Neville, 2003). We
undertook a randomised trial to test a more convenient single
radiation treatment.
METHODS
Patients
The eligibility criteria included: histological confirmation of MPM;
age greater than 18 years; and, a clearly identifiable procedure site.
Written informed consent was obtained from all trial patients. The
study had received institutional ethics committee approval.
Prophylactic radiation treatment
Patients were randomised after stratification by procedure type, to
receive either a single dose of electron beam chest wall radio-
therapy or no prophylactic therapy. A dose of 10Gy in a single
fraction was delivered to the chest wall, using 9-MeV electrons.
The dose was prescribed at 100%. No bolus was used. Radio-
therapy was given within 15 days of thoracic procedures.
Data collection and follow-up
In all cases, the site of the procedure was recorded, tattooed
and photographed, to allow accurate subsequent assessment.
Physicians assessed patients clinically for masses in the region
of the procedure, at 3 and 6 months, then 6-monthly until
death. Acute and late radiation toxicities were assessed and
graded according to the RTOG/EORTC criteria (Cox et al,
1995). Patients were assessed for early radiation toxicity at
1 week by the treating radiation oncologists, and
subsequently for late radiation effects by the respiratory
physicians.
Statistical methods
The primary outcome measure of the trial was procedure
tract metastasis. No effect on overall survival of the patients was
expected. The trial was designed with 80% power to detect a 20%
reduction in tract metastasis with prophylactic chest wall
irradiation (i.e. from an expected 20 to 0%) at the 5% one-sided
alpha significance level. The estimated number of tract metastases
following prophylactic RT was based on three published studies,
all reporting no failures. The calculated minimum sample size
of 54 sites was increased to 58 to allow for patients who might be
lost to follow-up. Tract metastasis-free survival was defined from
the time of randomisation to the development of a clinically
apparent metastasis in the immediate region of the procedure site
or to the last follow-up information. Overall survival was defined
as the interval from the date of randomisation to the date of death
or the last follow-up information. The crude incidence of tract
metastasis in the two trial arms was compared using Fisher’s exact
test (this was one-tailed, as radiotherapy will not increase the rate
of tract metastasis). Tract metastasis-free survival was compared
by log rank testing. The crude tract failure rates for the three-
procedure strata were compared using a two-sided Fisher’s exact
test. All analyses were performed on an intent-to-treat basis, and
were performed with the use of SPSS (Chicago, IL) statistical
software.
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Between December 1997 and July 2003, 58 procedure sites were
registered into the trial, from 43 patients; 28 sites were randomised
to the prophylactic chest wall RT arm and 30 sites to the control
arm. In all, 10 patients had two, and one patient three, sites
separately randomised. The clinical characteristics of the 58 sites
are summarised in Table 1. Overall, 22 sites had undergone
thoracic drainage or thoracoscopy, nine sites Abrams needle and
27 sites fine needle aspiration (FNA) prior to randomisation. One
patient in the control arm was given prophylactic radiotherapy at
his request. The radiotherapy fields used ranged from 4- to 8-cm
diameter circles.
Both early and late toxicity following radiotherapy were mild
with no RTOG/EORTC grade 2, 3 or 4 reactions noted. The overall
median survival from randomisation was 8.7 months, with a 1-year
survival of 35%. Only seven patients remain alive.
There was no statistically significant difference in tract
metastasis between the two arms of the trial, with three (10%)
metastases in the control arm and two (7%) in the prophylactic RT
arm (P¼0.53). The freedom from tract metastasis survival for the
two arms was not significantly different on log rank testing
(P¼0.82). The crude rates of tract metastases overall were 22% for
Abrams needles, 9% for thoracic drains and 4% for FNA, and these
were not statistically significantly different (P¼0.23).
DISCUSSION
We performed a randomised controlled trial examining the effect
of a single dose of prophylactic chest wall radiotherapy following
invasive procedures in MPM. There was no statistically significant
difference in procedure tract metastases. Our study was relatively
large with precise follow-up, and included patients who had
undergone a range of procedures.
Tract metastases in the control arm of the trial were low. The
median rate in the literature following thoracoscopies is 19%.
Similar tract metastasis rates are reported for Abrams and other
large needles (Metintas et al, 1995; Roussel and Nouvet, 1995).
Pleurectomy and extra-pleural pneumonectomy have high rates of
chest wall failure without prophylactic RT (Rusch et al, 2001).
There is little information on tract metastasis following fine needle
aspiration, but in our study this procedure carried the lowest risk
of malignant seeding (although this was not statistically signifi-
cantly). The risk of seeding appears to be related to procedure and
technique.
A dose of 10Gy delivered in a single fraction using 9-MeV
electrons does not appear to be effective in preventing procedure
tract metastasis. The relative effective dose for different radiation
schedules can be estimated using the linear-quadratic model
(Muller-Runkel and Vijayakumar, 1991). For cancers, 10Gy in a
single fraction is equivalent to delivering 12Gy in six 2-Gy
fractions. For comparison, 21Gy in three fractions is equivalent to
approximately 42Gy in 21, 2-Gy fractions. That is, the dose we
used was equivalent to approximately 40% of the reported three-
fraction schedules. This lower dose could be expected to be less
effective, but the actual difference in outcome depends on
steepness of the tumour control probability curve. Our study
suggests a clinically important dose–response over this dose
range.
Another possible explanation for the lack of effect is that 9MeV
electrons might be inadequately penetrating. The French non-
randomised series and subsequent randomised trial used higher
energy 12–15MeV electrons (Boutin and Rey, 1993; Boutin et al,
1995), while the British study employed 140- or 250-kV photons
(Low et al, 1995). These alternative radiations give a higher dose
beyond approximately 3cm depth in tissue. However, 9 (or less)
MeV electrons successfully deliver post-mastectomy chest wall
radiotherapy (e.g. Morgan et al, 2002; Feigenberg et al, 2003), and
this seems a less likely explanation.
We did not demonstrate a benefit from a single dose of
prophylactic chest wall irradiation. We continue to recommend
prophylactic treatment to be used following high-risk procedures,
delivering 21Gy in three fractions.
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Table 1 The characteristics of sites registered on study
RT arm (n¼28) Control (n¼30) Overall
Number (%) Number (%)
Age (years)
Mean 70.0 70.0
Range 53.7–85.1 51.0–86.3
Sex
Male 26 (93%) 29 (97%) 55
Female 2 (7%) 1 (3%) 3
Procedure
Thoracic drain/thoracoscopy 11 (39%) 11 (37%) 22
FNA 13 (46%) 14 (47%) 27
Abrams needle 4 (14%) 5 (17%) 9
RT given
28 (100%) 1 (3%)
Mesothelioma tract metastases
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